Abstract:OBJECTIVE:To determine whether lipid microspheres containing prostaglandin E1 (lipo-PGE1) improve pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension (PAH).METHODS:Forty-nine patients with PAH (8 patients with primary pulmonary hypertension, 21 patients with collagen vascular disease, 20 patients with congenital systemic-to-pulmonary shunts) were randomly classified into a conventional therapy group (n = 22) or a group receiving lipo-PGE1 plus conventional drugs (lipo-PGE1 group; n = 27). Echocardiographic pulmonary parameters, New York Heart Association (NYHA) functional class, and Bruce treadmill test results for exercise capacity were recorded before and after treatment.RESULTS:After 2 weeks of treatment with lipo-PGE1 (10 microg bid for 14 days), there were significant improvements in the values (+/- SD) for systolic pulmonary arterial pressure (SPAP) [76.9 +/- 27.9 mm Hg vs 66.5 +/- 22.8 mm Hg, p < 0.001]; total pulmonary resistance (27.2 +/- 13.3 dyne.s.cm(-5) vs 20.2 +/- 10.7 dyne.s.cm(-5), p < 0.001); left ventricular ejection fraction (58.7 +/- 9.6% vs 64.4 +/- 6.8%, p < 0.001); and cardiac output (3.1 +/- 0.8 L/min vs 3.7 +/- 1.1 L/min, p < 0.01). The NYHA functional class decreased from 3.0 +/- 0.6 to 2.5 +/- 0.6 (p < 0.001), and the exercise capacity increased from 2.8 +/- 1.0 to 4.3 +/- 1.3 metabolic equivalents (MET) [p < 0.001]. Compared with the conventional therapy group, the lipo-PGE(1) group achieved significant reduction of SPAP (10.4 +/- 10.3 mm Hg vs 2.2 +/- 5.6 mm Hg, p = 0.002) and a significant elevation of exercise capacity (1.5 +/- 0.9 MET vs 0.6 +/- 1.1 MET, p = 0.018).CONCLUSION:Lipo-PGE1 can decrease pulmonary artery pressure and increase exercise capacity in patients with PAH.

Curative effect of lipo-prostaglandin E1 on pulmonary hypertension in patient with chronic pulmonary heart disease

Effects of Lipo-Prostaglandin E1on Pulmonary Hemodynamics and Clinical Outcomes in Patients with Pulmonary Arterial Hypertension

The Clinical Study on Seventy Four Patients with Acute Pulmonary Contusion

Effectiveness of Prostaglandin E1on hypoxic pulmonary hypertension in pig

Paracrine Effects Of Bone Marrow-Derived Endothelial Progenitor Cells: Cyclooxygenase-2/Prostacyclin Pathway In Pulmonary Arterial Hypertension

Effects of liposomal prostaglandin E1 on fibrinolytic system in peri-percutaneous coronary interventional in acute coronary syndrome

Therapeutic effect of ipratropium bromide combined with long-term domiciliary oxygen therapy for patients with chronic obstructive pulmonary disease

Effect of Prostaglandin E1 on Acute Thromboembolic Pulmonary Hypertension

Effects of lipo-prostaglandin E1 Lipo-PGE1 on arterial oxygen partial pressure and intropulmonary shunt inpatients with controlled hypotension

Comparison of effectiveness of prostaglandin E1 and amrinone on hypoxic pulmonary hypertension in pigs

Clinical Effects of Liposome-Prostaglandin E1 on Acute Respiratory Distress Syndrome Induced by Trauma

Effects of Lipid Microspheres Prostaglandin E1 on Microcirculation Deficit of Subarachnoid Hemorrhage

Clinical investigation on the effects of lipo-prostaglandine1 E1 in sudden deafness

Liposomal prostaglandin E1 improves the prognosis of 76 patients with acute ischemic stroke

Prostaglandin E1 in treatment of patients with early diabetic nephropathy

Effect of Inhaled Iloprost on Pulmonary Hypertension Related to Congenital Heart Disease After Cardiopulmonary Bypass

Effects of liposomal prostaglandin E1 on inflammatory cytokines at early stage of acute coronary syndrome

Effects of treprostinil on pulmonary arterial hypertension during surgery for congenital heart disease complicated with severe pulmonary arterial hypertension

Effects of Prostaglandin E_1 on Hyperoxia Induced Lung Injury in Neonatal Rats

Effect of iloprost on biomarkers in patients with congenital heart disease-pulmonary arterial hypertension.

Pulmonary endarterectomy (PEA): the treatment for chronic thromboembolic pulmonary hypertension (CTEPH)